The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Targeting ALDHbright Human Carcinoma–Initiating Cells with ALDH1A1-Specific CD8+ T Cells
Open accessAbstract
Purpose: Cancer-initiating cells (CIC) are considered to represent the subpopulation of tumor cells that is resistant to conventional cancer treatments, highly tumorigenic in immunodeficient mice, and responsible for tumor recurrence and metastasis. Based on an elevated aldehyde dehydrogenase (ALDH) activity attributable to ALDH1/3 isoforms, ALDHbright cells have been identified and isolated from tumors and shown to have characteristics of CIC. The ALDH1A1 isoform was previously identified as a tumor antigen recognized by CD8+ T cells. This study examines the ability of ALDH1A1-specific CD8+ T cells to eliminate ALDHbright cells and control tumor growth and metastases. Experimental Design: ALDHbright cells were isolated by flow cytometry using ALDEFLUOR from HLA-A2+ human head and neck, breast, and pancreas carcinoma cell lines and tested for their tumorigenicity in immunodeficient mice. ALDH1A1-specific CD8+ T cells were generated in vitro and tested for their ability to eliminate CICs in vitro and in vivo by adoptive transfer to immunodeficient mice bearing human tumor xenografts. Results: ALDHbright cells isolated by flow cytometry from HLA-A2+ breast, head and neck, and pancreas carcinoma cell lines at low numbers (500 cells) were tumorigenic in immunodeficient mice. ALDHbright cells present in these cell lines, xenografts, or surgically removed lesions were recognized by ALDH1A1-specific CD8+ T cells in vitro. Adoptive therapy with ALDH1A1-specific CD8+ T cells eliminated ALDHbright cells, inhibited tumor growth and metastases, or prolonged survival of xenograft-bearing immunodeficient mice. Conclusions: The results of this translational study strongly support the potential of ALDH1A1-based immunotherapy to selectively target CICs in human cancer. Clin Cancer Res; 17(19); 6174–84. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Suhoski, M. M., Golovina, T. N., Aqui, N. A., Tai, V. C., Varela-Rohena, A., Milone, M. C., Carroll, R. G., Riley, J. L., & June, C. H. (2007) · Molecular Therapy · doi:10.1038/mt.sj.6300134 · Cited by 266
Cited by
Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment
Phi, L. T. H., Sari, I. N., Yang, Y.-G., Lee, S.-H., Jun, N., Kim, K. S., Lee, Y. K., & Kwon, H. Y. (2018) · Stem Cells International · doi:10.1155/2018/5416923 · Cited by 994
Clara, J. A., Monge, C., Yang, Y., & Takebe, N. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0293-2 · Cited by 752
Chen, T., You, Y., Jiang, H., & Wang, Z. Z. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25797 · Cited by 560
Sun, T., Yang, W., Toprani, S. M., Guo, W., He, L., DeLeo, A. B., Ferrone, S., Zhang, G., Wang, E., Lin, Z., et al. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-019-0507-3 · Cited by 74
Self-citationDifferentiation Therapy Targeting the β-Catenin/CBP Interaction in Pancreatic Cancer
Manegold, P., Lai, K., Wu, Y., Teo, J.-L., Lenz, H.-J., Genyk, Y., Pandol, S., Wu, K., Lin, D., Chen, Y., et al. (2018) · Cancers · doi:10.3390/cancers10040095 · Cited by 51
Metadata
- Authors
- Visus, C., Wang, Y., Lozano-Leon, A., Ferris, R. L., Silver, S., Szczepanski, M. J., Brand, R. E., Ferrone, C. R., Whiteside, T. L., Ferrone, S., DeLeo, A. B., & Wang, X.
- Venue
- Clinical Cancer Research
- Published
- 2011-10-01
- Volume
- 17
- Issue
- 19
- Pages
- 6174-6184
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2115316834
- Cited by
- 162
- References
- 1
- FWCI
- 4.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting ALDHbright Human Carcinoma–Initiating Cells with ALDH1A1-Specific CD8+ T Cells. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-11-1111
- The paper
- Visus, C., Wang, Y., Lozano-Leon, A., Ferris, R. L., Silver, S., Szczepanski, M. J., Brand, R. E., Ferrone, C. R., Whiteside, T. L., Ferrone, S., DeLeo, A. B., & Wang, X. (2011). Targeting ALDHbright Human Carcinoma–Initiating Cells with ALDH1A1-Specific CD8+ T Cells. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-11-1111
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.